Newsletter Tool

To view this email as a web page, click here

Today's Rundown

After WHO trial failure, influential medical group advises against Gilead's remdesivir in COVID critical care: Reuters
Insurers' strong financial performance continues in third quarter as they brace for a potentially rocky Q4
J&J tops list of healthcare supply chains amid COVID vaccine effort—and Pfizer wins kudos, too
Synairgen stock climbs on COVID-19 treatment results
Qiagen begins rolling out digital, portable COVID-19 antigen test hub
Mayo, Intermountain navigate ‘wild west’ of starting Hospital at Home during COVID-19 pandemic
Cleveland Clinic team draws a link between COVID-19 protection and the sleep aid melatonin
Biopharma roundup: Roche chairman backs vaccine mandate; China faces pressure to unveil shot data
Amwell posts 80% jump in Q3 revenue amid ongoing wave of telemedicine adoption

Featured Story

After WHO trial failure, influential medical group advises against Gilead's remdesivir in COVID critical care: Reuters

By Eric Sagonowsky

Gilead’s remdesivir, now known as Veklury, is perhaps the most successful COVID-19 drug so far. It scored a full FDA nod in October after months of emergency use and brought in $873 million last quarter. But an influential European medical association now says it shouldn't be used in intensive care patients.

Insurers' strong financial performance continues in third quarter as they brace for a potentially rocky Q4

By Paige Minemyer

Major national health insurers continued to largely turn a significant profit in the third quarter, though numbers didn't quite reach the sky-high figures reported in the first half of the year.

J&J tops list of healthcare supply chains amid COVID vaccine effort—and Pfizer wins kudos, too

By Kyle Blankenship

With a range of COVID-19 vaccine candidates nearing the finish line, more eyes are turning to the strength of drugmakers' supply chains to meet global demand. One of the drugmakers leading the pack—Johnson & Johnson—can tout a supply chain that's the best in its field, a new report finds.

Synairgen stock climbs on COVID-19 treatment results

By Nick Paul Taylor

Synairgen has shared more data from the COVID-19 clinical trial that sent its stock up 300% earlier this year. The latest update, which triggered a 30% jump in Synairgen’s shares, contains a closer look at the effect of inhaled nebulised interferon beta-1a SNG001 on hospitalized COVID-19 patients.

Qiagen begins rolling out digital, portable COVID-19 antigen test hub

By Conor Hale

Qiagen is preparing to launch its portable coronavirus antigen test, using a digital hub and up to eight test-stick cartridges to process more than 30 samples per hour.

Mayo, Intermountain navigate ‘wild west’ of starting Hospital at Home during COVID-19 pandemic

By Robert King

Mayo Clinic and Intermountain Healthcare detail their implementation of Hospital at Home programs and what new regulations and changes they need to ensure success of the home-based initiatives.

Cleveland Clinic team draws a link between COVID-19 protection and the sleep aid melatonin

By Angus Liu

Scientists are continuing to try to repurpose existing medicines as a fast approach to containing COVID-19. After analyzing a large patient registry, researchers at the Cleveland Clinic suggested that a popular over-the-counter sleep aid melatonin may be a possible option for the disease.

Biopharma roundup: Roche chairman backs vaccine mandate; China faces pressure to unveil shot data

By Eric Sagonowsky,Angus Liu,Kyle Blankenship,Conor Hale,Fraiser Kansteiner

An approved coronavirus shot should be mandatory, Roche's chairman said. China is facing pressure to reveal data on its vaccine candidates. Fosun got the OK to kick off a phase 2 trial of Pfizer and BioNTech's candidate in China. Israel secured 8 million Pfizer doses, and Switzerland launched a rolling review of Moderna's data.

Amwell posts 80% jump in Q3 revenue amid ongoing wave of telemedicine adoption

By Tina Reed

Here's what the company's CEO had to say about rising demand, it's latest product and its partnership with Google in its first earnings call since going public.

COVID-19 Tracker